Airiver Medical Receives FDA IDE Approval for Pivotal Trial of Drug-Coated Balloon in Central Airway Stenosis
核心洞察
Airiver Medical (搜索) received FDA investigational device exemption (IDE) approval to begin a pivotal clinical trial of its Pulmonary Drug Coated Balloon for treating central airway stenosis (搜索).
The nationwide study will enroll up to 200 patients to assess the safety and efficacy of the device that combines balloon dilation with localized paclitaxel delivery.
The technology aims to address an unmet medical need in treating recurrent airway stenosis, with approximately 100,000 tracheo-bronchial procedures performed annually in the United States.
Airiver Medical (搜索), a clinical-stage company focused on respiratory tract conditions, has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (搜索) to initiate a pivotal clinical trial of its Pulmonary Drug Coated Balloon (DCB) for treating benign central airway stenosis (搜索). This marks the company's first IDE study submission and approval.
Study Design and Patient Population
The nationwide study will enroll up to 200 patients suffering from central airway stenosis (搜索) to assess the safety and efficacy of the Airiver DCB technology. The device combines standard balloon dilation to open the respiratory tract with proprietary drug delivery designed to maintain symptom relief and prevent recurrence.
The proprietary coating enables very localized paclitaxel delivery to the stenosis while limiting drug levels in surrounding healthy tissue. The trial will test the Airiver DCB against standard of care bare balloon dilation.
Addressing an Unmet Medical Need
"As it stands, there is no optimal treatment of recurrent airway stenosis available as part of today's treatment paradigm," said Lixiao Wang, founder, chief executive officer and chief technology officer for Airiver Medical (搜索). "Securing IDE approval for this study is extremely exciting because the Airiver DCB has the potential to establish a new minimally invasive and durable treatment option preventing recurrence for patients suffering from this serious condition, which has not yet been accomplished."
Central airway stenosis (搜索), defined as airway narrowing, is often associated with prolonged intubation, tracheostomy, stenting, tuberculosis (搜索) or lung transplant. Approximately 100,000 tracheo-bronchial stenting and dilation procedures are performed annually within the United States.
Regulatory Pathway and Commercialization
The study will serve as the basis for Airiver Medical (搜索)'s regulatory submission to the FDA and eventual commercialization of the Airiver Pulmonary DCB in the U.S. The Airiver DCB is currently an investigational device for treating benign central airway stenosis (搜索) and has not received marketing authorization from the FDA.
Company Background
Airiver Medical (搜索) is developing technologies to help patients who suffer from certain respiratory tract conditions. The company aims to improve the current standard of care for central airway stenosis (搜索) and chronic rhinosinusitis (搜索). The Drug Coated Balloon technology could potentially offer sustained patency, better outcomes and fewer treatments for these conditions.